Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations
- 30 March 2012
- journal article
- Published by Elsevier
- Vol. 30 (24) , 3580-3586
- https://doi.org/10.1016/j.vaccine.2012.03.050
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Multiple Antigenic Sites Are Involved in Blocking the Interaction of GII.4 Norovirus Capsid with ABH Histo-Blood Group AntigensJournal of Virology, 2012
- Structural Analysis of Histo-Blood Group Antigen Binding Specificity in a Norovirus GII.4 Epidemic Variant: Implications for Epochal EvolutionJournal of Virology, 2011
- Chimpanzees as an animal model for human norovirus infection and vaccine developmentProceedings of the National Academy of Sciences, 2010
- Molecular Epidemiology of Genogroup II-Genotype 4 Noroviruses in the United States between 1994 and 2006Journal of Clinical Microbiology, 2010
- Evolutionary Dynamics of GII.4 Noroviruses over a 34-Year PeriodJournal of Virology, 2009
- Influenza vaccinesVaccine, 2009
- Herd Immunity to GII.4 Noroviruses Is Supported by Outbreak Patient SeraJournal of Virology, 2009
- Epochal Evolution of GGII.4 Norovirus Capsid Proteins from 1995 to 2006Journal of Virology, 2007
- Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteinsVirology, 2006
- Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env ImmunogenJournal of Virology, 2006